Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses

Oncogene

Volumn 36, Issue 44, 2017, Pages 6204-6212

  Torrente, L ^a   Sanchez, C ^a   Moreno, R ^a   Chowdhry, S ^a   Cabello, P ^a   Isono, K ^b   Koseki, H ^b   Honda, T ^c   Hayes, J D ^a   Dinkova Kostova, A T ^a   De La Vega, L ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Institute of Physical and Chemical Research   (Japan)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 2; HYDROGEN PEROXIDE; MESSENGER RNA; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; CARRIER PROTEIN; DOXORUBICIN; HIPK2 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

ARTICLE; BINDING SITE; CELL PROTECTION; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME INDUCTION; ENZYME REGULATION; GAIN OF FUNCTION MUTATION; GENE LOCUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; PLASMID; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION; A-549 CELL LINE; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

A549 CELLS; ANIMALS; APOPTOSIS; BINDING SITES; CARRIER PROTEINS; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICE; NF-E2-RELATED FACTOR 2; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85032962106     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.221     Document Type: Article

References (74)

1. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002; 4: 11-19.
2. Aikawa Y, Nguyen LA, Isono K, Takakura N, Tagata Y, Schmitz ML et al. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J 2006; 25: 3955-3965.
3. Isono K, Nemoto K, Li Y, Takada Y, Suzuki R, Katsuki M et al. Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals. Mol Cell Biol 2006; 26: 2758-2771.
4. Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J et al. HIPK2 represses beta-cateninmediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci USA 2007; 104: 13040-13045.
5. Iacovelli S, Ciuffini L, Lazzari C, Bracaglia G, Rinaldo C, Prodosmo A et al. HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif 2009; 42: 373-384.
6. de la Vega L, Hornung J, Kremmer E, Milanovic M, Schmitz ML. Homeodomaininteracting protein kinase 2-dependent repression of myogenic differentiation is relieved by its caspase-mediated cleavage. Nucleic Acids Res 2013; 41: 5731-5745.
7. Sjolund J, Pelorosso FG, Quigley DA, DelRosario R, Balmain A. Identification of Hipk2 as an essential regulator of white fat development. Proc Natl Acad Sci U S A 2014; 111: 7373-7378.
8. Dauth I, Kruger J, Hofmann TG. Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res 2007; 67: 2274-2279.
9. Calzado MA, de la Vega L, Moller A, Bowtell DD, Schmitz ML. An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response. Nat Cell Biol 2009; 11: 85-91.
10. de la Vega L, Grishina I, Moreno R, Kruger M, Braun T, Schmitz ML. A redoxregulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Mol Cell 2012; 46: 472-483.
11. Garufi A, Ricci A, Trisciuoglio D, Iorio E, Carpinelli G, Pistritto G et al. Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. Cell Death Dis 2013; 4: e639.
12. Giraud S, Diaz-Latoud C, Hacot S, Textoris J, Bourette RP, Diaz JJ. US11 of herpes simplex virus type 1 interacts with HIPK2 and antagonizes HIPK2-induced cell growth arrest. J Virol 2004; 78: 2984-2993.
13. Hofmann TG, Jaffray E, Stollberg N, Hay RT, Will H. Regulation of homeodomaininteracting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification. J Biol Chem 2005; 280: 29224-29232.
14. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F et al. MDM2- regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 2007; 25: 739-750.
15. de la Vega L, Frobius K, Moreno R, Calzado MA, Geng H, Schmitz ML. Control of nuclear HIPK2 localization and function by a SUMO interaction motif. Biochim Biophys Acta 2011; 1813: 283-297.
16. Saul VV, de la Vega L, Milanovic M, Kruger M, Braun T, Fritz-Wolf K et al. HIPK2 kinase activity depends on cis-autophosphorylation of its activation loop. J Mol Cell Biol 2013; 5: 27-38.
17. Choi DW, Na W, Kabir MH, Yi E, Kwon S, Yeom J et al. WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation. Mol Cell 2013; 51: 374-385.
18. Gresko E, Roscic A, Ritterhoff S, Vichalkovski A, del Sal G, Schmitz ML. Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J 2006; 25: 1883-1894.
19. Jin Y, Ratnam K, Chuang PY, Fan Y, Zhong Y, Dai Y et al. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med 2012; 18: 580-588.
20. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, Crone J et al. Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 2008; 10: 812-824.
21. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002; 4: 1-10.
22. Akaike Y, Kuwano Y, Nishida K, Kurokawa K, Kajita K, Kano S et al. Homeodomaininteracting protein kinase 2 regulates DNA damage response through interacting with heterochromatin protein 1gamma. Oncogene 2015; 34: 3463-3473.
23. Al-Beiti MA, Lu X. Expression of HIPK2 in cervical cancer: correlation with clinicopathology and prognosis. Aust N Z J Obstet Gynaecol 2008; 48: 329-336.
24. Schulten HJ, Hussein D, Al-Adwani F, Karim S, Al-Maghrabi J, Al-Sharif M et al. Microarray expression data identify DCC as a candidate gene for early meningioma progression. PLoS One 2016; 11: e0153681.
25. Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, Leonard JR et al. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008; 27: 4745-4751.
26. Imberg-Kazdan K, Ha S, Greenfield A, Poultney CS, Bonneau R, Logan SK et al. A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells. Genome Res 2013; 23: 581-591.
27. Lapin V, Shirdel EA, Wei X, Mason JM, Jurisica I, Mak TW. Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy. Oncogenesis 2014; 3: e133.
28. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322.
29. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003; 43: 233-260.
30. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76-86.
31. McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003; 278: 21592-21600.
32. Itoh K, Tong KI, Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 2004; 36: 1208-1213.
33. Lee OH, Jain AK, Papusha V, Jaiswal AK. An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance. J Biol Chem 2007; 282: 36412-36420.
34. Du W, Jiang Y, Zheng Z, Zhang Z, Chen N, Ma Z et al. Feedback loop between p66 (Shc) and Nrf2 promotes lung cancer progression. Cancer Lett 2013; 337: 58-65.
35. Jain A, Lamark T, Sjottem E, Larsen KB, Awuh JA, Overvatn A et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 2010; 285: 22576-22591.
36. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010; 13: 1713-1748.
37. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009; 15: 3423-3432.
38. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010; 220: 446-451.
39. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68: 1303-1309.
40. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012; 22: 66-79.
41. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
42. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135: 1358-1368, 1368.e1-4.
43. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010; 16: 3743-3753.
44. Sasaki H, Suzuki A, Shitara M, Hikosaka Y, Okuda K, Moriyama S et al. Genotype analysis of the NRF2 gene mutation in lung cancer. Int J Mol Med 2013; 31: 1135-1138.
45. Li QK, Singh A, Biswal S, Askin F, Gabrielson E. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet 2011; 56: 230-234.
46. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-109.
47. Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla K, Rogowska-Wrzesinska A et al. The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal 2014; 21: 2498-2514.
48. Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D et al. Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Radic Biol Med 2010; 48: 1338-1346.
49. Hailemariam K, Iwasaki K, Huang BW, Sakamoto K, Tsuji Y. Transcriptional regulation of ferritin and antioxidant genes by HIPK2 under genotoxic stress. J Cell Sci 2010; 123: 3863-3871.
50. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006; 3: e420.
51. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008; 105: 13568-13573.
52. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010; 38: 5718-5734.
53. Kawamoto Y, Nakamura Y, Naito Y, Torii Y, Kumagai T, Osawa T et al. Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes. 15-deoxy-delta(12,14)-prostaglandin j2-induced expression of glutathione S-transferases. J Biol Chem 2000; 275: 11291-11299.
54. Honda T, Yoshizawa H, Sundararajan C, David E, Lajoie MJ, Favaloro FG Jr. et al. Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. J Med Chem 2011; 54: 1762-1778.
55. Kalra S, Knatko EV, Zhang Y, Honda T, Yamamoto M, Dinkova-Kostova AT. Highly potent activation of Nrf2 by topical tricyclic bis(cyano enone): implications for protection against UV radiation during thiopurine therapy. Cancer Prev Res (Phila) 2012; 5: 973-981.
56. Kelleher MO, McMahon M, Eggleston IM, Dixon MJ, Taguchi K, Yamamoto M et al. 1-Cyano-2,3-epithiopropane is a novel plant-derived chemopreventive agent which induces cytoprotective genes that afford resistance against the genotoxic alpha, beta-unsaturated aldehyde acrolein. Carcinogenesis 2009; 30: 1754-1762.
57. Canet MJ, Merrell MD, Harder BG, Maher JM, Wu T, Lickteig AJ et al. Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene. Drug Metab Dispos 2015; 43: 93-99.
58. Shang Y, Doan CN, Arnold TD, Lee S, Tang AA, Reichardt LF et al. Transcriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-beta-TAK1- dependent mechanism. PLoS Biol 2013; 11: e1001527.
59. Berber S, Wood M, Llamosas E, Thaivalappil P, Lee K, Liao BM et al. Homeodomaininteracting protein kinase (HPK-1) regulates stress responses and ageing in C. elegans. Sci Rep 2016; 6: 19582.
60. Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 2013; 73: 4158-4168.
61. Ann EJ, Kim MY, Yoon JH, Ahn JS, Jo EH, Lee HJ et al. Tumor suppressor HIPK2 regulates malignant growth via phosphorylation of Notch1. Cancer Res 2016; 76: 4728-4740.
62. Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27: 5115-5123.
63. Giachino C, Boulay JL, Ivanek R, Alvarado A, Tostado C, Lugert S et al. A tumor suppressor function for Notch signaling in forebrain tumor subtypes. Cancer Cell 2015; 28: 730-742.
64. Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood 2014; 123: 2451-2459.
65. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003; 3: 756-767.
66. Munoz IM, Szyniarowski P, Toth R, Rouse J, Lachaud C. Improved genome editing in human cell lines using the CRISPR method. PLoS ONE 2014; 9: e109752.
67. Kelly VP, Ellis EM, Manson MM, Chanas SA, Moffat GJ, McLeod R et al. Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin B1-aldehyde reductase, the glutathione S-transferase A5 and P1 subunits, and NAD(P)H:quinone oxidoreductase in rat liver. Cancer Res 2000; 60: 957-969.
68. Kemmerer ZA, Ader NR, Mulroy SS, Eggler AL. Comparison of human Nrf2 antibodies: a tale of two proteins. Toxicol Lett 2015; 238: 83-89.
69. Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T et al. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/beta-TrCP axis. Mol Cell Biol 2012; 32: 3486-3499.
70. Pi J, Bai Y, Reece JM, Williams J, Liu D, Freeman ML et al. Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med 2007; 42: 1797-1806.
71. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res 2012; 40: 7416-7429.
72. Dayalan Naidu S, Sutherland C, Zhang Y, Risco A, de la Vega L, Caunt CJ et al. Heat shock factor 1 is a substrate for p38 mitogen-activated protein kinases. Mol Cell Biol 2016; 36: 2403-2417.
73. Prochaska HJ, Santamaria AB. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 1988; 169: 328-336.
74. Faul F, Erdfelder E, Lang A-G, Buchner A. G∗Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-191.